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BACKGROUND: The incidence of nasopharyngeal carcinoma (NPC) has been historically low in the United States. Although etiological  
factors differ by histological subtype, Epstein-Barr virus is accepted as the primary risk factor for nonkeratinizing NPC. In light of the 
changing epidemiology of viral-associated cancers, it is important to evaluate the temporal incidence of NPC in the United States. 
METHODS: Incidence and survival data from 1973 through 2015 were obtained from the Surveillance, Epidemiology, and End Results 
program. Stratified analyses were conducted to assess temporal trends in NPC by histological subtype, sex, and race. The data were ana-
lyzed using SAS and Joinpoint Regression Software to determine age-adjusted incidence rates, determine trends in the annual percent 
change, and calculate 5-year relative survival estimates and Kaplan-Meier curves. RESULTS: Although overall NPC incidence is decreas-
ing in the United States, the nonkeratinizing differentiated subtype is starkly increasing, with an annual percent change of approximately 
4% among white males (95% CI, 2.5%-5.2%), white females (95% CI, 1.9%-6.2%), and black males (95% CI, 2.0%, 5.7%); 2.7% among black 
females (95% CI, 0.8%, 4.6%); and 1.8% among women in the “other” race category (95% CI, 0.4%-3.3%). Racial disparities were noted, 
with 32% of nonkeratinizing NPC cases among blacks occurring before the age of 40 years. In addition, black males displayed consist-
ently worse survival across all histological subtypes, whereas individuals in the “other” race category, particularly females, experienced 
the highest 5-year relative survival estimates. CONCLUSIONS: The current results indicate that the Epstein-Barr virus–related, differenti-
ated NPC subtype is increasing across all sexes and races in the United States, with distinct incidence and survival disparities among 
blacks. Cancer 2020;126:121-130. © 2019 American Cancer Society. 
KEYWORDS: disparity, Epstein-Barr virus, incidence, nasopharyngeal carcinoma, Surveillance, Epidemiology, and End Results (SEER), 
survival.
INTRODUCTION
Nasopharyngeal carcinoma (NPC) incidence varies greatly throughout the world. Although historically rare in the United 
States, NPC is endemic to southeast China, Southeast Asia, the Middle East, and North Africa.1 Arising from the sur-
face epithelium of the posterior nasopharynx,2 NPC is currently classified by the World Health Organization (WHO) 
into 3 major histological subtypes: keratinizing squamous cell carcinoma (WHO type 1), nonkeratinizing carcinoma 
(WHO type 2), which can further be divided into differentiated and undifferentiated, and basaloid squamous cell carci-
noma (WHO type 3).3 These pathological classifications have been repeatedly correlated with clinicopathologic features, 
treatment response, and prognosis,4,5 Basaloid squamous cell carcinoma is infrequent and thus is rarely reported in the 
literature.6 Nonkeratinizing NPC predominates in endemic regions, whereas the keratinizing subtype is most frequently 
observed in nonendemic regions, such as the United States.7 The unique geographic and ethnic distribution of NPC inci-
dence throughout the world suggests a multifactorial etiology that involves viral, genetic, and environmental components.
NPC incidence has been reported to rise monotonically with age in nonendemic countries; whereas, in high-risk 
populations, such as southern China, incidence peaks between ages 45 and 54 years among both sexes, suggesting that 
early exposure to carcinogens and Epstein-Barr virus (EBV) may result in younger onset NPC.8 EBV, a herpesvirus 
most commonly known for causing mononucleosis, is generally accepted as the primary etiologic factor in nonkera-
tinizing NPC. Increased latent EBV infection has been reported in dysplastic nasopharyngeal epithelium and NPC, 
suggesting that the infection occurs in the early stages of carcinogenesis.9-12 Because of the ubiquitous nature of infec-
tion and the disproportionate global case distribution of NPC, several studies have assessed interactions between EBV 
and other lifestyle risk factors in high-risk populations. Dietary factors, namely, early life exposure to Cantonese salted 
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dried fish and other preserved foods containing volatile 
N-nitrosamines, have been implicated in NPC carcino-
genesis both through the activation of latent EBV13 and 
as independent carcinogens.14
In nonendemic regions like the United States, cig-
arette smoking and heavy alcohol consumption have 
been associated with keratinizing squamous cell carci-
noma.15 Compared with never-smokers, heavy smok-
ers reportedly have a 2-fold to 4-fold increased risk of 
NPC.15-22 Several studies have suggested that the effect 
conferred by smoking and alcohol primarily pertains 
to those diagnosed when older than 50 years, suggest-
ing a differing etiology among younger patients.15 The 
increased prevalence of high-risk human papillomavirus 
(HPV) in oropharyngeal cancer etiology, paired with 
the similarities exhibited between the lymphoid and 
epithelium tissue of the oropharynx and nasopharynx, 
has led to investigations into the role of HPV in naso-
pharyngeal carcinogenesis. Although the results remain 
inconsistent, largely because of small sample sizes, 
there is evidence to suggest the role of HPV, and even 
HPV/EBV coinfection, in NPC.4,23-26
It is important to evaluate the incidence of NPC in 
the United States over time in light of the changing epi-
demiology of HPV-associated oral cancers. Thus, in these 
analyses, we assess NPC incidence and mortality trends 
in the United States from 1973 through 2015 using data 
from the Surveillance, Epidemiology, and End Results 
(SEER) program. In doing so, we aim to identify poten-
tial variation across race and sex and draw on the litera-
ture to make inferences on changing etiology over time.
MATERIALS AND METHODS
Data Selection and Criteria
Cancer incidence and survival data were obtained from 
the SEER program. For this analysis, data from the SEER 
9 registries were used, which include data from the fol-
lowing registries: Atlanta, Connecticut, Detroit, Hawaii, 
Iowa, New Mexico, San Francisco-Oakland, Seattle-
Puget Sound, and Utah registries. Data from 1973 
through 2015 were available for all sites, with the excep-
tion of Seattle-Puget Sound and Atlanta, which joined in 
1974 and 1975, respectively. Corresponding population 
estimates were obtained from SEER*Stat 8.3.5 data,27 
which are based on the US Census Bureau’s Population 
Estimates Program.28 In addition to diagnoses, case infor-
mation included age, sex, race, date of diagnosis, SEER 
historical staging, histology, cause of death classification, 
and survival time in months. Because of the small sample 
size of American Indians/Alaska Natives, this race group 
was combined with Asians/Pacific Islanders to create the 
“other” race grouping.
Tumor site and histology were identified according 
to the International Classification of Diseases for Oncology 
third edition (ICD-O-3).6,29 Histologic subtypes for 
NPC (site codes C11.0-C11.9) included: keratinizing 
squamous cell carcinoma (ICD-O histology codes 8070 
and 8071), differentiated nonkeratinizing carcinoma 
(ICD-O histology codes 8072 and 8073), undifferenti-
ated nonkeratinizing carcinoma (ICD-O histology codes 
8020, 8021, and 8082), and “carcinoma not otherwise 
specified” (ICD-O histology code 8010).5 In accordance 
with WHO guidelines, differentiated and undifferenti-
ated nonkeratinizing carcinomas were analyzed both sep-
arately and jointly to comprise the single nonkeratinizing 
group. Overall NPC was defined as the culmination of all 
the aforementioned histological groupings. Basaloid squa-
mous cell carcinomas (ICD-O histology code 8083) were 
excluded from these analyses because of the small sample 
size (N = 30). Additional exclusion criteria included un-
known race, nonmalignant carcinoma, and prior diagno-
sis of malignancy. Patient characteristics were assessed by 
histological subgrouping, and further evaluation of age at 
diagnosis (in 5 year groupings) was conducted by visually 
displaying case frequencies by race for overall, keratiniz-
ing, and nonkeratinizing NPC.
Sex-stratified exploratory analyses assessing inci-
dence trends in extranodal natural killer (NK)/T-cell 
lymphoma, nasal type (ICD-O histology code 9719), 
were conducted for all effective years, from 2001 through 
2015, to further evaluate the potential role of EBV in US 
malignancies.
Incidence Trends
Age-adjusted incidence rates (standardized to the US pop-
ulation) and annual percent change (APC) were assessed 
using a log-linear model stratified by race, sex, and his-
tological classification in Joinpoint Regression Program 
version 4.5.0.1.30 Joinpoint uses a Monte Carlo permu-
tation method to assess the number of joinpoints along 
with the slope in the trends as well as their corresponding 
significance.31 In circumstances for which no cases were 
reported within a given year, a half-case was added to the 
age strata with the largest population to enable computa-
tion on the log-linear scale.31,32 SAS 9.4 software27 was 
used to shape the data and generate descriptive statistics.
Survival Analysis
Individual-level data from the SEER*Stat case listing 
session was used to create Kaplan-Meier curves in SAS 
9.4 software. Graphs were sex-specific, stratified by 
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histologic type, and strata were compared using log-rank 
tests. Patients whose survival data were obtained from 
death certificates or autopsy only, as well as those with 
unknown survival duration, were excluded. In addi-
tion, patients with unknown age or those with a previ-
ous invasive cancer diagnosis were excluded from survival 
analyses. Five-year relative survival, calculated as the ratio 
of the observed survival for patients with NPC to the 
expected survival rate based on age, race, and calendar 
year, were computed using the Kaplan-Meier method in 
SEER*Stat. Expected survival life tables were constructed 
using the US Decennial Life Tables from the National 
Center for Health Statistics and from the US Annual Life 
Tables from the National Center for Health Statistics for 
the years 2001 through 2014.27
RESULTS
Between 1973 and 2015, 4447 cases of NPC were re-
ported among males, and 1838 were reported among 
females in the United States. Regardless of histological 
subtype, males accounted for approximately 70% of the 
overall cancer burden. In general, the peak incidence oc-
curred at age 55 years for both sexes, with the undifferen-
tiated nonkeratinizing carcinoma subgroup representing 
the youngest mean age at diagnosis (49.34 and 49.15 years 
for males and females, respectively). Expository analyses 
revealed a bimodal distribution among blacks, with 25% 
of all patients being diagnosed at age <40 years compared 
with 12% and 21% of their white and other race counter-
parts, respectively. Although this trend was not apparent 
for patients with keratinizing NPC, 32% of nonkeratiniz-
ing NPCs among blacks, 21% among whites, and 22% 
among the other race group occurred at age <40  years 
(see Supporting Fig. 2). The keratinizing squamous cell 
carcinoma subtype made up the majority of NPC cases, 
largely because of its predominance among white pa-
tients, who accounted for 49% of the overall sample size. 
Nonkeratinizing NPC was diagnosed more frequently 
among blacks and predominated among the other race 
group. Among those with nonkeratinizing NPC, the 
undifferentiated cell type was more frequently reported 
across all races. SEER summary stage was available for 
cases diagnosed before 2004, and most cases were diag-
nosed as regional disease (Table 1).
Although incidence rates for the overall popu-
lation appeared to have remained relatively stagnant 
among males (APC, −0.2%; 95% CI, −0.4%, 0.1%) 
and females (APC, −0.4%; 95% CI, −0.8%, 0.0%), 
these trends varied greatly across both race and histol-
ogy. At the beginning of the study period, the expected 
age-standardized rates (EASRs) for white and black males 
were 0.67 and 0.66 per 100,000, respectively. White and 
black females both had notably lower rates, with EASRs 
of 0.34 and 0.16 per 100,000, respectively. The other race 
category, largely comprised of Asians/Pacific Islanders, ex-
hibited the highest NPC rates, with EASRs of 4.79 and 
1.76 per 100,000 among males and females, respectively. 
Temporal assessment of NPC incidence revealed signif-
icant decreases among white males (APC, −1.2%; 95% 
CI, −1.5%, −0.8%) and females (APC, −1.6%; 95% CI, 
−2.1%, −1.0%), black females (APC, −1.4%; 95% CI, 
−2.5%, −0.4%), as well as males (APC, −1.0%; 95% 
CI, −1.4%, −0.6%) and females (APC, −1.3%; 95% CI, 
−1.9%, −0.7%) in the other race category (Table 2).
These observed decreases in overall NPC were 
largely attributable to declines in the predominant ke-
ratinizing squamous cell carcinoma subtype. Joinpoint 
regression results for the overall population exhibited 
nonsignificant increases in keratinizing carcinoma among 
men from 1973 through 1985 (APC, 1.1%; 95% CI, 
−1.2%, 3.5%), followed by a significant decrease from 
1985 to 2015 (APC, −2.6%, 95% CI, −3.2%, −2.1%), 
and similar declines were observed among women (APC, 
−2.4%; 95% CI, −3.0%, −1.7%). Although this pattern 
of reduced keratinizing NPC was seen across all races, it 
was not found to be significant among black males and 
demonstrated the greatest impact among males (APC, 
−3.4%; 95% CI, −4.1%, −2.7%) and females (APC, 
−4.2%; 95% CI, −5.1%, −3.2%) in the other race cate-
gory (Table 2).
Nonkeratinizing NPC revealed 2 very different pat-
terns in incidence trends, depending on histological sub-
type. Undifferentiated carcinomas significantly decreased, 
with an APC of approximately −2% among white males 
(95% CI, −2.8%, −1.3%) and females (95% CI, −3.0%, 
−0.6%), −2.7% among black females (95% CI, −4.2%, 
−1.1%), −1.5% among males in the other race category 
(95% CI, −2.2%, −0.6%), and −2.4% among women 
in the other race category (95% CI, −3.5%, −1.4%). 
The differentiated subtype, conversely, increased starkly 
in incidence, with an APC of approximately 4% among 
white males (95% CI, 2.5%-5.2%), white females (95% 
CI, 1.9%-6.2%), and black males (95% CI, 2.0%-5.7%); 
2.7% among black females (95% CI, 0.8%-4.6%); and 
1.8% among women in the other race category (95% CI, 
0.4%-3.3%). This dichotomy in incidence between dif-
ferentiated and undifferentiated led to an attenuation in 
the overall trends of nonkeratinizing NPC (Table 2).
Exploratory analyses of incidence trends in extran-
odal NK/T-cell lymphoma, nasal type, revealed trends 
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very similar to those apparent in differentiated nonke-
ratinizing NPC. Between 2001 and 2015, incidence 
increased for among both sexes, with an APC of 3.2% 
(95% CI, 0.7%-5.8%) among males and 3.9% (95% 
CI, 0.2%-7.8%) among females. Race-stratified analysis 
demonstrated even steeper increases among white males 
(APC, 3.8%; 95% CI, 0.6%-7.1%) and females (APC, 
4.1%; 95% CI, 0.7%-7.6%). No significant increases 
were noted for the other race groups, likely because of 
small sample sizes within these groups.
Five-year relative survival estimated by race, sex, and 
histological subtype can be found in Table 3. For all NPC 
types, 5-year relative survival was 53.0% among males 
and 55.8% among females. Figure 1 displays sex-stratified 
Kaplan-Meier survival plots by histological subgrouping. 
Both male and female patients who had keratinizing 
squamous cell carcinoma had the worst survival com-
pared with those who had the other histological subtypes 
(log-rank P < .001). The 5-year relative survival rates for 
keratinizing squamous cell carcinoma were 41.9% and 
41.5% for males and females of all races, respectively. 
Whereas black males had consistently poorer survival 
across all histological subtypes, individuals in the other 
race category, particularly females, had the highest 5-year 
relative survival estimates (Table 3).
DISCUSSION
This is the first study, to our knowledge, to assess tem-
poral changes in NPC incidence in the United States. 
Although overall NPC incidence appears to be decreas-
ing in the United States, the EBV-related differentiated 
nonkeratinizing NPC subtype is increasing at a concern-
ing rate among all race groups and sexes in the United 
States. NPC has long been considered a relatively rare dis-
ease in the United States, with a reported incidence rate 
<1 per 100,000.2,33,34 Nevertheless, in endemic regions, 
NPC remains a major public health problem, with annual 
incidence rates exceeding 20 per 100,000 individuals.33 
Several studies have previously reported decreased inci-
dence of NPC in successive generations of Chinese mi-
grants to the United States35; however, the EASR among 
those belonging to the other race category, of which 98% 
identify as Asians/Pacific Islanders, remain >5 times 
higher in females and 7 times higher among males com-
pared with their white counterparts. In addition, the rate 
of change in overall NPC incidence, represented as the 
APC, between the white and other race individuals re-
mained comparable throughout the study period, leading 
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EBV, a prominent etiological factor in NPC, is 
a ubiquitous virus that infects and persists latently in 
>90% of the global population.36 Although primary in-
fection is often subclinical, EBV replication can occur 
in oropharyngeal epithelial cells37 as well as B lympho-
cytes in normal and malignant nasopharyngeal tissue,38 
EBV-encoded RNA has repeatedly been detected in both 
premalignant and malignant tissues of primarily nonkera-
tinizing NPC39-41; nevertheless, few studies, particularly 
in nonendemic countries, have characterized the potential 
differences in etiology between differentiated and undif-
ferentiated NPC. It has also been demonstrated that anti-
body titers, particularly for IgA, not only precede cancer 
development42 but are associated with prognosis and re-
currence.43 A considerable amount of research has been 
conducted to determine whether particular strains of EBV 
may explain, at least in part, the international patterns of 
NPC.44-47 Several different sequence variations have been 
detected in the oncogenic viral latent membrane protein 
1 (LMP1) of EBV in NPC tumors44,48-50; however, there 
remains no strong evidence to suggest an increased risk as-
sociated with different EBV variants.33,49-52 In the current 
study, we found that differentiated nonkeratinizing NPC 
incidence was increasing among all sex and race groups, 
leading to speculation of an increased role of EBV in NPC 
in the United States. Exploratory analyses into SEER inci-
dence trends of extranodal NK/T-cell lymphoma, a form 
of non-Hodgkin’s lymphoma consistently associated with 
EBV,53-67 demonstrated significant increases in this can-
cer type among both sexes over this time period, further 
supporting the possibility of an increasing role in EBV 
etiology in US malignancies (see Supporting Fig. 1).
In certain endemic populations, such as the 
Cantonese, early age incidence peaks in NPC are generally 
associated with childhood consumption of, or even tradi-
tional weaning by,68 salted fish and other preserved foods 
high in volatile N-nitrosamines.1 Early life infection by 
EBV,69,70 as well as genetic predisposition, have both been 
proposed as possible risk factors for early onset NPC, but 
little consensus has been reached regarding the etiology of 
such cases in the United States. Although the average age 
at diagnosis in our study was 55 years for both sexes, we 
noted a bimodal distribution in cases among blacks, with 
25% of patients being diagnosed before age 40 years com-
pared with 12% of their white counterparts. Whereas this 
distribution has been observed previously,35 we noted that 
this disparity was particularly apparent in the nonkeratiniz-
ing subtype, in which 32% of cases among blacks occurred 
before age 40 years (see Supporting Fig. 2). Although we 
are unable to definitively conclude that the increase in 
these young-onset cases is caused by EBV alone, EBV se-
roprevalence has been reported to be significantly higher 
among African American youth compared with their white 
peers.71,72 Further studies are needed to properly assess 
the role childhood infection by EBV as well as possible 
gene-environment interactions in the US population.
The majority of case-control studies report a 
2-fold to 4-fold increased risk of NPC among smok-
ers.15,16,18-22 Vaughan et al estimated that two-thirds of 
keratinizing NPCs in the United States are attributable 
Figure 1. Kaplan-Meier survival curves illustrate overall survival by sex and morphology. NOS indicates not otherwise specified; SCC, 
squamous cell carcinoma.
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to smoking, whereas both subtypes of nonkeratinizing 
carcinoma failed to demonstrate significant associa-
tions.15 Decreases in smoking prevalence in the United 
States73 may explain the decreases in keratinizing squa-
mous cell carcinoma seen in our analyses. Diet, which 
has been the primary nonviral exposure associated with 
NPC in endemic regions, has been postulated to affect 
NPC primarily through the consumption of preformed 
nitrosamines or nitrosamine precursors.74 Although 
cultural differences in dietary patterns preclude early 
and repeated exposure to salted fish,75 harissa, quad-
did, and touklia76 from US dietary etiology, preserved 
meats, which contain high levels of added nitrites, have 
been studied and have not been significantly associated 
with NPC carcinogenesis.74 Although that particu-
lar study did not assess genetic variation, it has been 
shown that individuals possessing the c2/c2 metabolic 
genotype for CYP2E1, a catalytic enzyme for the meta-
bolic activation of low-molecular-weight nitrosamines, 
experience a 2.6-fold increased risk of NPC compared 
with those possessing 1 or 2 copies of the wild-type al-
lele.77 Moreover, alcohol, in addition to its innate role 
as a carcinogen,15,18 has been shown in animal mod-
els to increase the carcinogenicity of ingested nitrosa-
mines,78,79 further stressing the importance of dietary 
interaction studies in the understanding of nasopharyn-
geal carcinogenesis.
Our study confirmed previous reports of a survival 
advantage of the undifferentiated nonkeratinizing mor-
phology over the differentiated nonkeratinizing and ke-
ratinizing squamous cell NPCs.5,35 In addition, we found 
that the other racial grouping had consistently improved 
survival compared with white and black patients, particu-
larly among those presenting with keratinizing squamous 
cell carcinoma; these findings are consistent with other 
reports of a survival advantage among Chinese/Asian 
patients.5,35,80 One proposed rationale for this observa-
tion may be the high proportion of polymorphisms in 
the epidermal growth factor receptor (EGFR) found in 
the Chinese/Asian population, leading to lower EGFR 
expression and, consequently, improved prognosis.5,81-84
Several limitations are present in the current study. 
Although the use of SEER-9 data allows for temporal 
analysis of cancer trends since 1973, it represents only 
one-half of the participating registries to date. In ad-
dition, population estimates used for trends analyses 
were only available for the white, black and other race 
categories until 1990, resulting in our inability to assess 
age-adjusted NPC incidence trends in specific other 
races (American Indian/Alaska Native and Asian/Pacific 
Islander) or by Hispanic ethnicity for the entire study 
period. Treatment variables, particularly those perti-
nent to NPC, such as chemotherapy and radiation, are 
not suggested for use by SEER because of known data 
gaps for these variables. The absence of data regarding 
comorbidities, smoking, drinking behavior, and EBV 
prevalence limits our ability to make definitive state-
ments regarding the underlying etiology influencing 
the observed trends. Although more precise treatment 
and comorbidity variables are available by linking the 
SEER database to the Medicare claims database, the 
majority of patients with NPC in this study were too 
young to qualify for Medicare (aged <65 years). Trends 
in adenocarcinoma of the nasopharynx, largely associ-
ated with occupational exposures like wood dust,85-87 
were not able to be assessed because of small sample 
sizes. Finally, the WHO classification system for NPC 
had changed several times throughout the study period, 
consequently leading to concerns regarding the inter-
pretability of subtype-specific results. That said, the 
changes within the WHO guidelines were made in the 
grouping of the subtypes, not the pathology; this study 
uses morphology codes to define NPC subtypes; there-
fore, the changes in WHO classifications have no effect 
on the study or the conclusions.
Although NPC remains relatively rare in the overall 
US population, the EBV-related differentiated subtype 
is increasing across all sexes and races. Many studies as-
sessing nonkeratinizing NPC, particularly in the United 
States, aggregate differentiated and undifferentiated carci-
noma because of the lack of a sufficient sample size; the 
results of the current study highlight the need for addi-
tional research to elucidate the potential etiological differ-
ences between these histological subgroups, consequently 
addressing the rationale for the disparity in the observed 
incidence trends. Because prospective cohort studies 
with comprehensive exposure assessment would require 
decades to recruit a sufficient sample size to assess gene- 
environment interactions, multicenter studies or case- 
control studies in high-incidence regions may prove to 
be a more feasible method to improve understanding of 
NPC etiology. In addition, studies evaluating the biolog-
ical mechanism by which EBV is involved in NPC are 
needed to move EBV preventative and targeted therapeu-
tic methods forward, such as immunotherapy or even an 
EBV vaccine. Recent interest in the possible role of HPV 
in NPC, likely representing subepithelial extension from 
the oropharynx because of the lack of anatomical con-
straints in Waldeyer ring,1 also may aid in understand-
ing incidence trends and NPC pathogenesis. Finally, a 
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comprehensive characterization of risk factors among 
young adults is needed to reveal the cause for the adoles-
cent incidence peak observed in African American popu-
lations in this study.
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